I
Ibtissam Marchiq
Researcher at University of Nice Sophia Antipolis
Publications - 16
Citations - 1212
Ibtissam Marchiq is an academic researcher from University of Nice Sophia Antipolis. The author has contributed to research in topics: Basigin & Medicine. The author has an hindex of 9, co-authored 11 publications receiving 985 citations. Previous affiliations of Ibtissam Marchiq include Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors
Renaud Le Floch,Johanna Chiche,Ibtissam Marchiq,Tanesha Naiken,Karine Ilc,Clare Murray,Susan E. Critchlow,Danièle Roux,Marie-Pierre Simon,Jacques Pouysségur +9 more
TL;DR: Findings highlight that the major protumoral action of CD147/Basigin is to control the energetics of glycolytic tumors via MCT1/MCT4 activity and that blocking lactic acid export provides an efficient anticancer strategy.
Journal ArticleDOI
Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H+ symporters
TL;DR: The metabolic pathways generating lactate are reviewed, the rationale for targeting lactic acid transporter complexes for the development of efficient and selective anticancer therapies are discussed, and interest in lactate for cancer development appears recently.
Journal ArticleDOI
Genetic Disruption of Lactate/H+ Symporters (MCTs) and Their Subunit CD147/BASIGIN Sensitizes Glycolytic Tumor Cells to Phenformin
TL;DR: It is highlighted that inhibition of the MCT/BSG complexes alone or in combination with phenformin provides an acute anticancer strategy to target highly glycolytic tumors.
Journal ArticleDOI
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
Erik O. Pettersen,Peter Ebbesen,Peter Ebbesen,Roben G. Gieling,Kaye J. Williams,Ludwig Dubois,Philippe Lambin,Carol Ward,James Meehan,Ian Kunkler,Simon P. Langdon,Anne Hansen Ree,Kjersti Flatmark,Heidi Lyng,Maria J. Calzada,Luis del Peso,Manuel O. Landázuri,Agnes Görlach,Hubert Flamm,Jochen Kieninger,Gerald Urban,Andreas Weltin,Dean C. Singleton,Syed Haider,Francesca M. Buffa,Adrian L. Harris,Andrea Scozzafava,Claudiu T. Supuran,Isabella Moser,Gerhard Jobst,Morten Busk,Kasper Toustrup,Jens Overgaard,Jan Alsner,Jacques Pouysségur,Johanna Chiche,Nathalie M. Mazure,Ibtissam Marchiq,Scott K. Parks,Afshan Ahmed,Margaret Ashcroft,Silvia Pastorekova,Yihai Cao,Kasper M.A. Rouschop,Brad Wouters,Marianne Koritzinsky,Hilda Mujcic,Dan Cojocari +47 more
TL;DR: A large-scale collaborative EU-financed project 2009–2014 denoted METOXIA has studied all the mentioned aspects of hypoxia with the aim of selecting potential targets for new hypoxIA-specific therapy and develop the first stage of tests for this therapy.
Journal ArticleDOI
Na+/H+ antiporter (NHE1) and lactate/H+ symporters (MCTs) in pH homeostasis and cancer metabolism
TL;DR: A fully-coupled mathematical model is used to simulate the relative contribution of the Na(+)/H(+)-exchanger NHE1 and the monocarboxylate transporters in response to lactate production, as it occurs in highly hypoxic and glycolytic tumor cells.